CEMI - Chembio Diagnostics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Chembio Diagnostics, Inc.

3661 Horseblock Road
Medford, NY 11763
United States

IndustryDiagnostic Substances
Full Time Employees131

Key Executives

Mr. John J. Sperzel III, B.Sc.CEO, Pres & Director475kN/A54
Mr. Richard J. LarkinCFO & Exec. VP259.69kN/A62
Mr. Javan EsfandiariChief Science & Technology Officer and Exec. VP422.64kN/A51
Mr. Michael K. SteeleVP of Sales, Marketing & Bus. Devel.240.91kN/A53
Ms. Sharon KlugewiczPres of Americas Region332.78kN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Chembio Diagnostics, Inc., together with its subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company's products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV 1/2 Assay Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a DPP HIV-Syphilis multiplex test for the detection of antibodies to HIV and syphilis; and a test for the detection of Hepatitis-C. Chembio Diagnostics, Inc. sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; and collaboration with an international diagnostics company to develop a POC diagnostic test for a specific type of cancer. It also has a collaboration with AstraZeneca to develop a POC diagnostic test to detect an undisclosed biomarker. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Corporate Governance

Chembio Diagnostics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.